Blinatumomab
Based on 3 publication(s) in Google Scholar
Blinatumomab (Anatumomab) is a bispecific monoclonal antibody with two binding sites, one for CD3E on T cells and one for CD19 on B cells. Blinatumomab can be used in research for acute lymphoblastic leukemia.
For research use only. We do not sell to patients.
- Purity: 97.33%
- CAS No.: 853426-35-4
- Molecular Weight:54.09 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications Citing Use of MedChemExpress (MCE) Blinatumomab
More-
Others
Biological Activity
(scFv-kappa-heavy)-(scFv-heavy-kappa)
Human
CD19 & CD3E
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:leukemic nonobese diabetic SCID mouse model (20 days old)[2]
-
Dosage:0.01-1 μg
-
Administration:Intravenous injection (i.v.), once daily for 5 days
-
Result:Caused none of the animals developed detectable tumors and survived inoculation of NALM-6 cells at cumulative doses of 5 or 0.5 μg for the entire observation period of 76 days. Cumulative doses of 0.05 and 0.005 μg were not effective in preventing tumor growth.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
(scFv-kappa-heavy)-(scFv-heavy-kappa)
ELISA, FACS, Functional assay
-
Loaded Blinatumomab on CM5 Chip, can bind CD19 Protein, Human (CHO, Fc, HY-P7333) with an affinity constant of 11.02E-9 M as determined in SPR assay. -
Flow cytometric analysis of 1×106 Jurkat cells labelling CD3E (red) with Blinatumomab (HY-P9963). Cells were fixed with 4% paraformaldehyde and permeabilised with 90% methanol. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Alexa Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa Isotype Control (HY-P99001, blue) was used as the isotype control.
Chemical Information
-
CAS No. 853426-35-4
-
Appearance Liquid
-
Molecular Weight 54.09 kDa
-
Color Colorless to light yellow
-
SMILES
[Blinatumomab]
-
Synonyms
bscCD19xCD3; AMG-103; MEDI-538; MT-103; BLINCYTO
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (3)
-
Journal Impact Factor
-
Most Recent
-
Cell Rep Med
Glycoengineering-based anti-PD-1-iRGD peptide conjugate boosts antitumor efficacy through T cell engagement. [Abstract]2024 Jun 18;5(6):101590. PMID: 38843844
Blinatumomab purchased from MedChemExpress. Usage Cited in: Cell Rep Med. 2024 Jun 18;5(6):101590. [Abstract]
Histogram of the percentage of conjugated cells when 2 × 105 Dye 670-stained NY-ESO-1157-165-primed HLA-A∗0201-Raji cells were cocultured 1 h with mixed 2 × 104 CFSE-stained 1G4-PD-1-Jurkat cells and 2 × 104 Dye 450-stained PD-1-Jurkat cells. The concentration of αPD-1-(iRGD)2 was 10 μg/mL, while Blinatumomab (1 μg/mL; 1 h) .
-
bioRxiv
Single injection of modified self-amplifying RNA encoding a CD19 bispecific T cell engager mediates long-term malignant B cell clearance. [Abstract]2026 Apr 19:2026.04.18.719371. PMID: 42039561 -
Purity & Documentation
-
Data Sheet (262 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Kantarjian H, et, al. Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia. N Engl J Med. 2017 Mar 2;376(9):836-847. [Content Brief]
[2]. Dreier T, et al. T cell costimulus-independent and very efficacious inhibition of tumor growth in mice bearing subcutaneous or leukemic human B cell lymphoma xenografts by a CD19-/CD3- bispecific single-chain antibody construct. J Immunol. 2003 Apr 15;170(8):4397-402. [Content Brief]
[3]. Hoffman LM, et al. Blinatumomab, a Bi-Specific Anti-CD19/CD3 BiTE(®) Antibody for the Treatment of Acute Lymphoblastic Leukemia: Perspectives and Current Pediatric Applications. Front Oncol. 2014 Mar 31;4:63. [Content Brief]
[4]. Zhang R, et al. The establishment and application of CD3E humanized mice in immunotherapy[J]. Experimental Animals, 2022, 71(4): 442-450. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)